Yin Rui, Cheng Juanli, Wang Jingyao, Li Panxin, Lin Jinshui
Shaanxi Key Laboratory of Chinese Jujube, College of Life Sciences, Yan'an University, Yan'an, Shaanxi Province, China.
Front Microbiol. 2022 Aug 26;13:955286. doi: 10.3389/fmicb.2022.955286. eCollection 2022.
, a Gram-negative bacterium, is one of the major pathogens implicated in human opportunistic infection and a common cause of clinically persistent infections such as cystic fibrosis, urinary tract infections, and burn infections. The main reason for the persistence of infections is due to the ability of to secrete extracellular polymeric substances such as exopolysaccharides, matrix proteins, and extracellular DNA during invasion. These substances adhere to and wrap around bacterial cells to form a biofilm. Biofilm formation leads to multiple antibiotic resistance in , posing a significant challenge to conventional single antibiotic therapeutic approaches. It has therefore become particularly important to develop anti-biofilm drugs. In recent years, a number of new alternative drugs have been developed to treat infectious biofilms, including antimicrobial peptides, quorum-sensing inhibitors, bacteriophage therapy, and antimicrobial photodynamic therapy. This article briefly introduces the process and regulation of biofilm formation and reviews several developed anti-biofilm treatment technologies to provide new directions for the treatment of biofilm infection.
作为一种革兰氏阴性菌，是引起人类机会性感染的主要病原体之一，也是临床上持续性感染（如囊性纤维化、尿路感染和烧伤感染）的常见病因。感染持续存在的主要原因是在入侵过程中能够分泌细胞外聚合物物质，如胞外多糖、基质蛋白和细胞外DNA。这些物质附着并包裹细菌细胞形成生物膜。生物膜的形成导致对多种抗生素产生耐药性，给传统的单一抗生素治疗方法带来重大挑战。因此，开发抗生物膜药物变得尤为重要。近年来，已开发出多种新型替代药物来治疗感染性生物膜，包括抗菌肽、群体感应抑制剂、噬菌体疗法和抗菌光动力疗法。本文简要介绍了生物膜形成的过程和调控，并综述了几种已开发的抗生物膜治疗技术，为生物膜感染的治疗提供新方向。
